WALTHAM, Mass., Oct. 1, 2019 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO), the world leader in serving science,
has completed its previously announced acquisition of an active
pharmaceutical ingredient (API) manufacturing facility from
GlaxoSmithKline (GSK) for €90 million. Completion of the
transaction follows the receipt of all required regulatory
approvals.
Approximately 400 employees at the Cork, Ireland, site will become part of
Thermo Fisher's Pharma Services
business within its Laboratory Products and Services Segment.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with revenues of more than $24
billion and approximately 70,000 employees globally. Our
mission is to enable our customers to make the world healthier,
cleaner and safer. We help our customers accelerate life sciences
research, solve complex analytical challenges, improve patient
diagnostics, deliver medicines to market and increase laboratory
productivity. Through our premier brands – Thermo Scientific,
Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab
Services – we offer an unmatched combination of innovative
technologies, purchasing convenience and comprehensive services.
For more information, please visit www.thermofisher.com.
Media Contact Information:
Ron O'BrienPhone:
781-622-1242
E-mail: ron.obrien@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-gsk-manufacturing-site-in-cork-ireland-300928140.html
SOURCE Thermo Fisher Scientific